Last reviewed · How we verify
BMS-790052 (Daclatasvir)
Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.
Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread. Used for Chronic hepatitis C virus infection (genotype 1-6), Hepatitis C in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | BMS-790052 (Daclatasvir) |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | NS5A inhibitor |
| Target | Hepatitis C virus NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Daclatasvir is a direct-acting antiviral that targets the NS5A protein, a multifunctional regulator essential for hepatitis C virus replication and assembly. By binding to NS5A, it prevents the formation of the viral replication complex and inhibits both RNA replication and virion assembly, leading to rapid suppression of viral load.
Approved indications
- Chronic hepatitis C virus infection (genotype 1-6)
- Hepatitis C in treatment-naïve and treatment-experienced patients
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
- Insomnia
Key clinical trials
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (NA)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
- Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (PHASE2)
- Antiviral Agents Against COVID-19 Infection (PHASE2, PHASE3)
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-790052 (Daclatasvir) CI brief — competitive landscape report
- BMS-790052 (Daclatasvir) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI